NASDAQ · Medical - Devices

DCTH (DCTH) Stock

$15.11 -2.33% NASDAQ: DCTH Healthcare

Valuation

MetricValue
Price$15.11
Market Cap$521.62M
P/E Ratio157.43
P/B Ratio3.43
P/S Ratio4.21
EPS (TTM)$0.00
52-Week High$15.11
52-Week Low$8.12
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE2.70%
ROA2.42%
ROCE0.89%
Gross Margin0.00%
Operating Margin1.18%
Net Margin0.62%
Debt/Equity0.01
Current Ratio10.91

Annual Financials (USD)

Metric20212022202320242025
Revenue$4.0M$3.0M$2.0M$37.0M$85.0M
Operating Profit$-25.0M$-34.0M$-38.0M$-12.0M$1.0M
Net Profit$-26.0M$-37.0M$-48.0M$-26.0M$3.0M
EPS$-3.59$-4.12$-2.94$-0.93$0.07
Op Margin-690.0%-1245.0%-1849.0%-33.4%0.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$33.0M$18.0M$39.0M$77.0M$124.0M
Total Liabilities$21.0M$24.0M$23.0M$8.0M$12.0M
Cash$23.0M$8.0M$13.0M$32.0M$43.0M
Borrowings$16.0M$16.0M$10.0M$1.0M$1.0M

Latest News

HEPZATO-KIT Market Forecast to 2034 Highlights Growth Drivers, Sales Potential and Competitive Landscape Across the 7MM GlobeNewswire · Jul 14, 2026 Delcath Systems Doses First Patient in Mid-Stage Trial of Hepzato MT Newswires · Jul 9, 2026 Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer Business Wire · Jul 9, 2026 Delcath (DCTH) Q1 2026 Earnings Transcript Motley Fool · May 8, 2026 Delcath Systems Q1 Earnings Call Highlights MarketBeat · May 7, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-23.0M$-25.0M$-31.0M$-19.0M$23.0M
Investing Cash Flow$0$0$-20.0M$-2.0M$-28.0M
Financing Cash Flow$2.0M$0$35.0M$43.0M$-6.0M
Net Cash Flow$-2.0M$-15.0M$1.0M$20.0M$11.0M
Free Cash Flow$-23.0M$-25.0M$-31.0M$-19.0M$21.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA338.43
FCF Yield5.05%
Quick Ratio10.33
Interest Coverage—
Return 1Y7.06%
Return 3Y157.88%
Return 5Y37.29%

Ownership

Insiders Held8.13%
Institutions Held49.02%
Institutions Float Held53.36%
Institutional HolderSharesReport Date
Vanguard Capital Management LLC1,329,2882026-03-31
Blackrock Inc.1,784,4662026-03-31
Private Wealth Advisors, LLC591,5242026-03-31
Rosalind Advisors, Inc.3,300,3892026-03-31
Propel Bio Management, LLC979,6982026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AGL $99.07 +0.11% -3.60 $1.65B 0.00%
BWAYBrainsWay Ltd. $16.56 +2.54% 72.48 $649.53M 0.00%
CERS $2.32 +2.20% -34.25 $467.54M 0.00%
MASS $8.30 -1.31% 12.81 $340.53M 0.00%
NAKA $4.96 +15.89% -0.62 $86.31M 0.00%

About DCTH

DCTH is led by CEO Gerard J. Michel, employs 96 people, headquartered in US, publicly traded since 2018.

DCTH stock trades at $15.11 with a market capitalization of $521.62M. The stock is valued at a price-to-earnings (P/E) ratio of 157.43, price-to-book of 3.43, price-to-sales of 4.21. Over the past 52 weeks the stock has ranged between $8.12 and $15.11, and currently trades at its 52-week high.

On profitability, DCTH generates a return on equity (ROE) of 2.70%, return on capital employed of 0.89%, an operating margin of 1.18%, a net profit margin of 0.62%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides